{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:36:03Z","timestamp":1784874963476,"version":"3.55.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Lung cancer is a malignant tumor with the highest morbidity and mortality rate worldwide, and it seriously endangers human health. In recent years, immunotherapy has been widely used in lung cancer and has achieved great benefits, especially the application of promoting antitumor immune defense. However, immune-related adverse events (irAEs) caused by immune checkpoint inhibitors have received increasing attention, which largely limits their use. We report the first case of new acute mastitis caused by anti-PD1 inhibitors due to lung adenocarcinoma. A 65-year-old female patient came to our hospital for treatment with cough and shortness of breath for one month. Chest CT showed that the malignant tumor in the lower lobe of the right lung with pleural effusion had metastasized to many places, and then pleural effusion was taken for pathological examination. Pathological examination indicated that the pleural fluid originated from lung adenocarcinoma. Subsequently, the patient received platinum-containing dual-agent chemotherapy (carboplatin and pemetrexed disodium) combined with immunotherapy (camrelizumab). During treatment, the patient developed known adverse events and unreported acute mastitis. After stopping camrelizumab, the patient\u2019s mastitis gradually improved. Our case shows that acute mastitis might be a new adverse event after the use of camrelizumab. Since this new adverse event has not been reported, we hope that oncology medical workers can obtain insight from our case and use it as a reference for the identification and management of irAEs.<\/jats:p>","DOI":"10.3389\/fimmu.2022.939873","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T04:52:26Z","timestamp":1661403146000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: A case of acute mastitis associated with reactive cutaneous capillary endothelial proliferation after camrelizumab treatment: A new immune-related adverse event"],"prefix":"10.3389","volume":"13","author":[{"given":"Ping-Shang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer (CameL): A randomized, open-label, multicenter, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"Multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicenter, open-label, parallel-group, randomized, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCORT): A multicenter, randomized, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21630","article-title":"An update on the immune landscape in lung and head and neck cancers","volume":"70","author":"Carlisle","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1634\/theoncologist.2016-0164","article-title":"Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer","volume":"22","author":"O'Kane","year":"2017","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7150\/thno.50333","article-title":"From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer","volume":"11","author":"D'Andr\u00e9a","year":"2021","journal-title":"Theranostics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: Mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000517078","article-title":"PD-L1 testing in cytological non-small cell lung cancer specimens: A comparison with biopsies and review of the literature","volume":"65","author":"Mansour","year":"2021","journal-title":"Acta Cytol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S367978","article-title":"Cancer metastases from lung adenocarcinoma disappeared after molecular targeted therapy: A successfully clinical treatment experience","volume":"15","author":"Li","year":"2022","journal-title":"Pharmgenomics Pers Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.11.019","article-title":"Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy","volume":"52","author":"Osmani","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.922076","article-title":"Case report: Recombinant human endostatin plus chemotherapy for epidermal growth factor receptor-negative miliary lung adenocarcinoma","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2021.08.013","article-title":"Cisplatin nanoparticles possess stronger antitumor synergy with PD1\/PD-L1 inhibitors than the parental drug","volume":"135","author":"Shen","year":"2021","journal-title":"Acta Biomater"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving toward personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4255","article-title":"Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: First global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-020-00886-2","article-title":"Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.14366\/usg.15024","article-title":"Nonpuerperal mastitis masking preexisting breast malignancy: importance of follow-up imaging","volume":"35","author":"An","year":"2016","journal-title":"Ultrasonography"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001532","article-title":"Clinical practice guidelines for diagnosis and treatment of patients with nonpuerperal mastitis: Chinese society of breast surgery (CSBrS) practice guideline 2021","volume":"134","author":"Zhou","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-3-030-41596-9_7","article-title":"Mastitis, breast abscess, and granulomatous mastitis","volume":"1252","author":"Omranipour","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"20120657","DOI":"10.1259\/bjr.20120657","article-title":"Radiological and clinical features of adult nonpuerperal mastitis","volume":"86","author":"Tan","year":"2013","journal-title":"Br J Radiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/00015458.2006.11679876","article-title":"Granulomatous lobular mastitis: a rare chronic inflammatory disease of the breast which can mimic breast carcinoma","volume":"106","author":"Verfaillie","year":"2006","journal-title":"Acta Chir Belg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000905","article-title":"A chitosan-coated chamomile microparticles formulation to prevent radiodermatitis in breast: A double-blinded, controlled, randomized, phase II clinical trial","volume":"45","author":"Garbuio","year":"2022","journal-title":"Am J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.939873\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T04:52:29Z","timestamp":1661403149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.939873\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2022.939873"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.939873","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"article-number":"939873"}}